Thinking beyond immunotherapy: implementing a multimodal care plan to facilitate extended survival in stage IV melanoma.

The treatment of metastatic melanoma has been revolutionized with the introduction of immune checkpoint inhibitors, though approximately 50% of patients will progress at 12 months even with the most robust immunotherapy combinations. As these drugs a…

Preview only. Read the full abstract at the source